Journal article

Genetic Predictors of Circulating 25-Hydroxyvitamin D and Prognosis after Colorectal Cancer.

Sonja Neumeyer, Katja Butterbach, Barbara L Banbury, Sonja I Berndt, Peter T Campbell, Rowan T Chlebowski, Andrew T Chan, Edward L Giovannucci, Amit D Joshi, Shuji Ogino, Mingyang Song, Marjorie L McCullough, Haifa Maalmi, JoAnn E Manson, Lori C Sakoda, Robert E Schoen, Martha L Slattery, Emily White, Aung K Win, Jane C Figueiredo Show all

Cancer Epidemiology, Biomarkers and Prevention | American Association for Cancer Research | Published : 2020


Background: Low serum 25-hydroxyvitamin D [25(OH)D] concentrations in patients with colorectal cancer have been consistently associated with higher mortality in observational studies. It is unclear whether low 25(OH)D levels directly influence colorectal cancer mortality. To minimize bias, we use genetic variants associated with vitamin D levels to evaluate the association with overall and colorectal cancer–specific survival. Methods: Six genetic variants have been robustly identified to be associated with 25(OH)D levels in genome-wide association studies. On the basis of data from the International Survival Analysis in Colorectal Cancer Consortium, the individual genetic variants and a wei..

View full abstract


Awarded by NCI NIH HHS

Funding Acknowledgements

CPS-II: The authors thank the CPS-II participants and StudyManagement Group for their invaluable contributions to this research. The authors also acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the NCI Surveillance Epidemiology and End Results program.r Fred Hutch core grant: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704.r Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO): NCI, NIH, U.S. Department of Health and Human Services (U01 CA137088, R01 CA059045, R01 CA176272).r CPSII: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. This study was conducted with Institutional Review Board approval.r DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH117/1-1, HO5117/2-1, HE5998/2-1, KL 2354/3-1, RO 2270/8-1, and BR 1704/17-1); the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany; and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, and 01ER1505B).r DALS: NIH (R01 CA48998 to M.L. Slattery).r Harvard cohorts (HPFS, NHS, PHS): HPFS is supported by the NIH (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, and R35CA197735), NHS by the NIH (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993, and R35 CA197735), and PHS by the NIH (R01 CA042182).r PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, NCI, NIH.r PMH-SCCFR: NIH (R01 CA076366 to P.A. Newcomb and U01 CA074794 to J. Potter).r VITAL: NIH (K05 CA154337).r WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.